Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Hoffmann-La Roche
University Health Network, Toronto
Jiangsu HengRui Medicine Co., Ltd.
The Lymphoma Academic Research Organisation
Fudan University
Shanghai JMT-Bio Inc.
North Eastern German Society of Gynaecological Oncology
Peter MacCallum Cancer Centre, Australia
Memorial Sloan Kettering Cancer Center
University Hospital Southampton NHS Foundation Trust
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of Virginia
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
Sun Yat-sen University
Rigshospitalet, Denmark
US Oncology Research
Women and Infants Hospital of Rhode Island
M.D. Anderson Cancer Center
Istituto Clinico Humanitas
WiSP Wissenschaftlicher Service Pharma GmbH
Children's Oncology Group
SWOG Cancer Research Network